UTRN and Duchenne muscular dystrophy: Recently, research on DMD therapies, has focused on possible gene-based strategies, and a few of these are now reaching the phase II/III clinical trial stage, such as the upregulation of utrophin, the enhancement of muscle regeneration, and virus-mediated mini-dystrophin gene therapy [9].